INVEX Therapeutics Ltd
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II… Read more
INVEX Therapeutics Ltd (IXC) - Total Liabilities
Latest total liabilities as of December 2025: AU$176.49K AUD
Based on the latest financial reports, INVEX Therapeutics Ltd (IXC) has total liabilities worth AU$176.49K AUD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
INVEX Therapeutics Ltd - Total Liabilities Trend (2019–2025)
This chart illustrates how INVEX Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
INVEX Therapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of INVEX Therapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fertoz Ltd
AU:FTZ
|
Australia | AU$2.55 Million |
|
Kinetic Seas Incorporated
PINK:KSEZ
|
USA | $1.00 Million |
|
Sah Polymers Limited
NSE:SAH
|
India | ₹404.78 Million |
|
CIENA - Dusseldorf Stock Exchang
DU:CIE1
|
Germany | €2.68 Billion |
|
NETCLASS TECHNOLOGY INC Class A Ordinary Shares
NASDAQ:NTCL
|
USA | $7.83 Million |
|
Goyal Aluminiums Limited
NSE:GOYALALUM
|
India | ₹115.40 Million |
|
Tower Real Estate Investment Trust
KLSE:5111
|
Malaysia | RM273.90 Million |
|
Grand Kartech Tbk
JK:KRAH
|
Indonesia | Rp563.69 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down INVEX Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 26.76 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how INVEX Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for INVEX Therapeutics Ltd (2019–2025)
The table below shows the annual total liabilities of INVEX Therapeutics Ltd from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$220.59K | -48.89% |
| 2024-06-30 | AU$431.63K | -72.55% |
| 2023-06-30 | AU$1.57 Million | +56.58% |
| 2022-06-30 | AU$1.00 Million | +52.47% |
| 2021-06-30 | AU$658.61K | -67.32% |
| 2020-06-30 | AU$2.02 Million | +115.43% |
| 2019-06-30 | AU$935.49K | -- |